Medication Review: What is non-responder imputation and how is it utilized in clinical trials?
GHAPPcast7 Tammi 2025

Medication Review: What is non-responder imputation and how is it utilized in clinical trials?

Thank you to Johnson & Johnson for your support of this Medication Review Video Module.

Clinical trials play a crucial role in guiding treatment decisions, but the way missing data is handled can significantly impact the results. In this medication review video module, Whitney Steinmetz, NP, from Presbyterian Medical Group in Albuquerque, NM, explains the concept of non-responder imputation (NRI)—a widely used statistical method in clinical trials.

Non-responder imputation is a conservative approach used to address missing data by assuming that participants who drop out or have missing responses did not respond to treatment. This method helps prevent overestimating a therapy’s effectiveness, ensuring that clinical trial results remain reliable. However, it can also underestimate a treatment’s true impact, particularly if patients drop out for reasons unrelated to treatment failure. Understanding how this statistical method influences trial outcomes is essential for healthcare providers, as it directly affects the interpretation of treatment efficacy and patient care decisions.

By reducing bias and offering a straightforward approach to data analysis, non-responder imputation helps maintain the integrity of clinical trial results. However, its conservative nature can sometimes skew findings, making a treatment appear less effective than it actually is. This is why it’s important for clinicians to be aware of how missing data is managed in studies. If non-responder imputation was used, the reported effectiveness of a treatment might be a cautious estimate rather than a complete reflection of its potential benefits.

For more information please visit the GHAPP website or download the GHAPP ACE app.

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(161)

GHAPPcast: Recognizing and Managing Overt Hepatic Encephalopathy

GHAPPcast: Recognizing and Managing Overt Hepatic Encephalopathy

Thank you to Salix for their support on this podcast episode. In this GHAPP podcast, host Christina Hanson, FNP, welcomes Janet Gripshover, DNP, FNP-BC, MBA, for a practical discussion on recognizing ...

18 Elo 48min

FAQ: Counseling Patients on Overt Hepatic Encephalopathy

FAQ: Counseling Patients on Overt Hepatic Encephalopathy

Thank you to Salix for their support on this FAQ video module.In this FAQ video module, Natalie Oliver, PA-C, discusses how healthcare professionals can counsel patients and caregivers about overt hep...

11 Elo 4min

FAQ: Identifying & Diagnosing Overt Hepatic Encephalopathy

FAQ: Identifying & Diagnosing Overt Hepatic Encephalopathy

Thank you to Salix for their support on this FAQ video module. In this FAQ video module, Samantha Ramirez, NP-C, discusses how healthcare professionals can identify and diagnose overt hepatic encephal...

4 Elo 2min

Subgroup Analysis: Differences in Maintenance Dosing For UC and CD

Subgroup Analysis: Differences in Maintenance Dosing For UC and CD

Thank you to Johnson & Johnson for their support on this podcast episode. In this GHAPP podcast, Amy Stewart, NP, of Capital Digestive Care, introduces a practical inflammatory bowel disease discussio...

23 Heinä 7min

Medication Review: Efficacy & Safety of Risankizumab in Patients with Moderate to Severely Active UC

Medication Review: Efficacy & Safety of Risankizumab in Patients with Moderate to Severely Active UC

Thank you to AbbVie for their support of this Medication Review Video Module.In this medication review, Melissa Ferrari, PA, and Jennifer Hamilton, MSPAS, PA-C, provide a comprehensive overview of the...

30 Kesä 17min

Med Review: SEQUENCE Trial: Risankizumab vs Ustekinumab in Anti-TNF-Refractory Crohn’s Disease

Med Review: SEQUENCE Trial: Risankizumab vs Ustekinumab in Anti-TNF-Refractory Crohn’s Disease

Thank you to AbbVie for their support on this Medication Review Video Module. In this medication review, Sharon Dudley-Brown, CRNP, PhD from Johns Hopkins University and Angelina Collins, MSN, ANP-BC,...

9 Kesä 12min

FAQ: QUASAR Long Term Extension Interim Analysis

FAQ: QUASAR Long Term Extension Interim Analysis

Thank you to Johnson & Johnson for their support on this FAQ Video Module. In this educational video, Jamie Brogan, APRN, from Northwestern Medicine, reviews the latest QUASAR long-term extension data...

2 Kesä 4min

Medication Review: Guselkumab IV vs SC Formulation

Medication Review: Guselkumab IV vs SC Formulation

Thank you to Johnson & Johnson for their support on this Medication Review Video Module. In this quick educational video, Angelina Collins, NP, from the University of California San Diego Inflammatory...

28 Touko 3min

Suosittua kategoriassa Terveys ja hyvinvointi

unicast
tiedenaiset-podcast
rss-pitaisko-erota
psykopodiaa-podcast
vakeva-elama-viisaampi-mieli-vahvempi-keho
voi-hyvin-meditaatiot-2
paritellen
terapiassa
meditaatiot-suomeksi
rss-pt-paahtio
rss-seksicast
rss-vapaudu-voimaasi
rss-kuumilla-aalloilla
selviytyjat-tarinoita-elamasta
rss-mighty-finland-podcast
rss-uplevel-by-sonja-hannus
ruokaklinikka
junnut-pelissa
leikitaanko-laakaria
katilon-kahvitunti